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In¯ammatory dendritic epidermal cells present in
skin lesions of the atopic eczema/dermatitis syn-
drome display the highest expression of the high-
af®nity receptor for IgE (FceRI), ever detected on
human antigen-presenting cells. Owing to the
instability of the FceRI (agg) complex and fast cleav-
age from the cell surface during the interleukin-4/
granulocyte-macrophage colony-stimulating factor
driven in vitro differentiation of monocytes, a
method to generate in¯ammatory dendritic epider-
mal cells was not at our disposal in the past and the
amount of ex vivo isolated in¯ammatory dendritic
epidermal cells available for functional assays was
limited. Therefore, information about the role of
in¯ammatory dendritic epidermal cells and FceRI on
this dendritic cell subtype in atopic and in¯amma-
tory skin diseases is completely missing. In this
study, we were able to: (i) increase the expression of
a functional FceRI complex on the cell surface of
immature monocyte-derived dendritic cells from
atopic donors by creating a reducing microenviron-
ment; (ii) enhance signi®cantly the intracellular pool
of the FceRIg chains, which is the limiting parameter
for the FceRI surface expression; and (iii) generate
monocyte-derived dendritic cells displaying the phe-
notypical characteristics of in¯ammatory dendritic
epidermal cells, producing high amounts of proin-
¯ammatory cytokines and chemokines similar to the
cytokines found in lesional skin of the atopic
eczema/dermatitis syndrome. Altogether the high
expression of functional FceRI on these cells enables
us for the ®rst time to study in¯ammatory dendritic
epidermal cells and FceRI-mediated mechanisms of
in¯ammatory dendritic epidermal cells in vitro, in
order to shed light on the putative role of this
important cell type in the atopic eczema/dermatitis
syndrome. Key words: atopic eczema/dermatitis syn-
drome/Fc receptors/FceRI/cysteine/redox state/human
dendritic cells/in¯ammatory dendritic epidermal cells. J
Invest Dermatol 119:842±849, 2002
T
he high-af®nity receptor for IgE (FceRI) represents
a key element on antigen-presenting cells, such as
Langerhans cells and dendritic cells (DC) (Bieber et
al, 1992; Wang et al, 1992; Maurer et al, 1995,
1998; Bieber, 1997; Novak et al, 2001b), mediating
cellular mechanisms in the blood and skin of patients suffering
from atopic diseases, such as allergic rhinitis, allergic asthma, or
atopic eczema/dermatitis syndrome (AEDS) (Johansson et al,
2001). One of the hallmarks of these cells is the expression of
the high-af®nity receptor for IgE, FceRI. The highest
expression of FceRI on antigen-presenting cells could be
detected on the so-called in¯ammatory dendritic epidermal cells
(IDEC) in lesional skin of AEDS patients (Wollenberg et al,
1995, 1996). Recent concepts support the hypothesis that IDEC
are of monocytic origin and can be recruited into the epidermis
by signals released from cells of the in¯ammatory micromilieu
in the acute phase of AEDS. Beside the high- and low-af®nity
receptor for IgE and the low-af®nity receptor for IgG (FcgRII),
IDEC express CD1a, CD1b, CD1c, CD11a, CD11b, CD11c,
the thrombospondin receptor (CD36), the mannose receptor
(CD206), the costimulatory molecules CD80, CD86, and
CD40, major histocompatibility complex (MHC) class I, and
MHC class II; however, in contrast to epidermal Langerhans
cells, IDEC lack the typical Birbeck granules and are Langerin
and Lag negative (Wollenberg and Bieber, 1998; Schuller et al,
2001). Interestingly, after successful topical treatment, the
number of IDEC in epidermal skin lesions decreases below
the detection level, further implying that this cell type is closely
related to the state of in¯ammation of the skin (Wollenberg et
al, 2001). Owing to the instability of the FceRI receptor
complex of ex vivo isolated and in vitro generated DC (Kraft et
al, 1998), IDEC could not be generated in vitro so far and a
reliable in vitro model has not been developed until now,
limiting our knowledge in this ®eld of research. A mandatory
parameter for the regulation of the FceRI surface expression on
human antigen-presenting cells is the amount of the intracel-
lular, disul®de-linked g-chain dimers, which associate with the
mature, terminally glycosylated a-chain in the Golgi compart-
ment and are transported as a complete trimeric FceRI (agg)
complex to the cell surface (Kraft et al, 1998; Kinet, 1999;
Albrecht et al, 2000). In the absence of a suf®cient amount of
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g-chains, the immature a-chain remains mainly localized in the
endoplasmic reticulum. In contrast to the a-chain, the g-chain
is not a unique feature of FceRI and is required for other Fc
receptor complexes, such as FcgRI (CD16) or the g-chain of
the T cell receptor complex (Kinet, 1999). Recently, Meuer et
al (Sido et al, 2000) could show that reducing agents are able to
stabilize the redox-sensitive disul®de dimers of the T cell
receptor complex of T lymphocytes and protect it from rapid
degradation in an oxidative milieu. In view of these ®ndings,
we assumed similar redox-sensitive mechanisms for the main-
tenance of FceRI on the cell surface of DC in vitro and
investigated, whether reducing agents could stabilize FceRI and
prevent the rapid cleavage of the receptor complex during the
in vitro culture. Furthermore, we developed an in vitro system to
generate IDEC from FceRIpos human monocytes of atopic
donors, which were similar to the IDEC found in lesional skin
of AEDS. This in vitro model enables us to study this important
cell type in functional assays and get new insights into the
putative role of FceRI on these cells in AEDS.
MATERIALS AND METHODS
Patients and diagnostic criteria A total of 30 patients with atopic
diseases such as allergic rhinitis or the allergic form of AEDS with a
moderate to high IgE serum level (> 150 kU per liter) and nonatopic
healthy volunteers with low serum IgE levels (< 100 kU per liter) were
recruited. The protocol was approved by the local ethical committee.
AEDS was diagnosed according to the criteria of Hani®n and Rajka
(1980) and the criteria of the European Task Force (Johansson et al,
2001). Patients on ultraviolet therapy, on systemic or local
glucocorticosteroid treatment or taking anti-histamines were excluded
from this study.
Reagents Phycoerythrin (PE)-labeled T6/RD1 (mIgG1) monoclonal
antibody (MoAb) (Coultertronics, Krefeld, Germany) is directed against
CD1a.
MoAb 22E7 (mIgG1) (a kind gift from J. Kochan, (Roche Inc., Nutley,
NJ) reacts with the a-subunit of FceRI (Riske et al, 1991).
MoAb against FceRIa (3G6) was from UBI (Lake Placid, NY).
The polyclonal rabbit anti-serum against FceRIg was from UBI.
MoAb 4D8 (mIgG2b) against FceRIg was kindly provided by J. Kochan
(Schoneich et al, 1992).
Blocking antibody against FceRI (15-5) competitive with IgE was a kind
gift from J. Hakimi and J. Kochan, (Roche Inc., Nutley, NJ) (Riske et
al, 1991).
The MoAb against CD40 (5C3) (mIgG1), CD86 (IT2.2) (mIgG2b),
CD83 (HB15a) (mIgG2b), the mannose receptor (CD206) (mIgG1)
(19.2), and cutaneous lymphocyte antigen (IgM) were from Pharmingen
(Hamburg, Germany).
The MoAb against CD1b (4.A7.6) (mIgG2a), CD1c (L161) (mIgG1),
CD11a (25.3.) (mIgG1), CD11b (BEAR1) (mIgG1), CD11c (BU15)
(mIgG1), CD16 (3G8) (mIgG1), FceRII/CD23 (9P.25) (mIgG1),
FcgRII/CD32 2E1 (mIgG2a), CD36 (FA6-152) (mIgG1), CD54
(84H10) (mIgG1), CD58 (AICD58) (mIgG2a), CD80 (MAB104)
Figure 1. Enhanced FceRI surface expression of dendritic cells in vitro could be achieved by incubation with 50 mM 2-ME. (A) The surface
expression of FceRI of monocytes (day 0) and dendritic cells on day 8 of the IL-4/GM-CSF driven culture of atopic and nonatopic donors generated
in the presence of 50 mM 2-ME (black boxes) or in the absence of 50 mM 2-ME (gray triangles) is shown. The percentage of FceRI positive CD14 (on
day 0 of culture in the presence of 2-ME) or CD1a positive cells (on day 8 of culture) is indicated on the y-axis, the time of culture (days) is indicated
on the x-axis. Taken together, dendritic cells generated from monocytes of atopic donors display a higher surface expression of the high-af®nity
receptor for IgE (FceRI) on day 8 of culture in the presence of 2-ME, than dendritic cells generated from monocytes of nonatopic donors; n = 20
atopic donors and n = 15 nonatopic donors; **p < 0.001. (B/C) The FceRI surface expression of monocytes on day 0 and day 8 of culture without
(Contr.) and with 2-ME of an atopic (B) and nonatopic (C) donor is shown as overlay histogram; this is one representative experiment of n = 20 for
atopic and n = 15 for nonatopic donors.
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(mIgG1), human IgE (De2) (E124.2.8) (mIgG1), Langerin (CD207)
(DCGM4) (mIgG1), E-cadherin (67A4) (mIgG1), and HLA-DR (G46-
6) (mIgG2a) were from Immunotech (Marseille, France).
The hybridoma cell line that produces MoAb W6/32 against MHC class
I (Barnstable et al, 1978) was kindly provided by Dr N. Koch (Institute
of Zoophyoiology, University of Bonn).
Fluorescein isothiocyanate (FITC)-labeled (F(ab¢)2 fragments of goat
anti-mouse antibody and donkey anti-rabbit antibody were purchased
from Jackson ImmunoResearch Laboratories (West Grove, PA).
Unlabeled and PE-labeled IgG1 and IgG2 was from Becton Dickinson
(Mountain View, CA).
PE-labeled antibody against interleukin (IL)-1a, tumor necrosis factor-a,
monocyte chemoattractant protein 1, monocyte chemoattractant protein
3, macrophage in¯ammatory protein a, and RANTES (Regulated on
Activation, Normal T cell Expressed and Secreted) were from
Pharmingen.
PE-labeled MoAb against IL-1b was from R&D systems (Wiesbaden,
Germany). Rabbit anti-human IgE was purchased from Dako (Glostrup,
Denmark).
Human myeloma IgE was obtained from Calbiochem (Bad Soden,
Germany).
PE-labeled anti-CD14 antibody and FITC-labeled anti-CD1a antibody
were from Becton Dickinson.
2-Mercaptoethanol (2-ME) and H2O2 were from Sigma-Aldrich, St.
Louis, MO.
Dithiothreitol (DTT) was from Gibco (Life Technologies, Paisley, U.K.).
Flow cytometric analysis Double staining experiments with saponin
or digitonin for the detection of the extracellular or intracellular
distribution of FceRI subunits were performed as described in detail
elsewhere (Kraft et al, 1998). Saponin permeabilization was used for the
detection of intracellular FceRIa, whereas digitonin permeabilization was
used for the detection of FceRIg expression. Cells were acquired using a
FACSCalibur ¯ow cytometer (Becton Dickinson). For quantitative
evaluation, the CD1a-positive population was gated manually and the
percentage of FceRIa or FceRIg-positive cells was determined using
Lysis II software (Becton Dickinson).
Immunolabeling for phenotyping was performed as reported before
(Novak et al, 2001c). Intracellular staining for cytokines and chemokines
was carried out according to the manufacturer's instructions. Brie¯y, cells
cultured in the presence of 1 mM per ml Brefeldin A (Pharmingen) were
®xed with 4% paraformaldehyde for 10 min, washed in phosphate-
buffered saline supplemented with 1% fetal bovine serum and 0.1%
sodium azide, and incubated for 30 min with 1 mg per ml FITC-
conjugated CD1a. Then the cells were washed with phosphate-buffered
saline containing 1% fetal bovine serum, 0.1% sodium azide, and 0.1%
saponin twice. The cells were incubated with PE-labeled MoAb
against cytokines or chemokines. After washing with phosphate-buffered
saline, cells were analyzed on a FACSCaliburâ (Becton Dickinson) as
described in detail elsewhere (Novak et al, 2001c). As a control, cells were
also stained with corresponding PE-labeled isotype-matched control
immunoglobulin. All incubations and washes were performed at 4°C.
Results are expressed as percentage positive cells and relative ¯uorescence
intensity (RFI) calculated from the mean ¯uorescence intensity (MFI) as
follows:
RFI = [MFI (cytokine/chemokine) ± MFI (control)]/MFI (control).
Isolation of epidermal cells and enrichment of Langerhans
cells Shave biopsies were taken from patients after obtaining signed
informed consent, according to the approval of the local ethics
committee. After local anesthesia, biopsies were taken from patients with
AEDS; chronic skin lesions, which had not been treated for 2 weeks
were sampled. AEDS was diagnosed according to the criteria of Hani®n
and Rajka (1980) and the new classi®cation of the European Task Force
(Johansson et al, 2001). Single cell suspensions were prepared from skin
biopsies by trypsinization as described previously (Wollenberg et al,
1999), washed with phosphate-buffered saline containing 1% fetal bovine
serum and 0.1% sodium azide, ®ltered through a 50 mm nylon mesh and
subjected to immunolabeling. Resistance of all receptor molecules to the
Figure 2. Reducing and oxidative agents in¯uence exclusively
FceRI expression of MoDC from atopic donors in vitro. MoDC
from atopic donors cultured for 8 d with IL-4 and GM-CSF (black bar;
Contr.) or additionally with 50 mM, 10 mM or 5 mM 2-ME (gray bars),
0.5 mM DTT (hatched bar) or H2O2 (white bar). The percentage of the
FceRI surface expression of CD1a-positive cells is indicated on the y-
axis; n = 5.
Figure 3. The amount of FeRIg is higher in IDEC. (A)
Semiquantitative reverse transcription±PCR revealed an increased
transcription of the FceRIg mRNA detectable in lysates obtained from
IDEC, whereas no differences in the signal for the FceRIa mRNA
transcripts of MoDC and IDEC could be detected. This is one
representative experiment of n = 4. (B) The extracellular expression of
the FceRI a-chain (white bars), the intracellular amount of FceRIa
(gray bars), and the amount of the FceRI g-chains (black bars) of MoDC
and IDEC on day 8 of culture is indicated as relative ¯uorescence index
(RFI) on the y-axis. These data demonstrate that the amount of FceRIg
is signi®cantly enhanced in IDEC, n = 6.
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limited trypsin digestion procedure had been established in preliminary
experiments.
Preparations and culture Whole blood was taken after obtaining
signed informed consent from patients with allergic forms of AEDS
(n = 30) according to the criteria of Hani®n and Rajka (Hani®n and
Rajka, 1980). Blood samples were obtained in accordance with local
ethics committee.
Monocytes from atopic donors were isolated from peripheral blood
with a modi®ed density gradient protocol after using Nycoprepâ
(Nycomed, Oslo, Norway). Brie¯y, red blood cells were separated from
plasma by sedimentation from whole ethylenediamine tetraacetic acid
blood with 1 : 10 (w/v) 6% Dextran 500 in 0.9% NaCl. Plasma was
gently layered over Nycoprepâ and centrifuged for 20 min at 600 3 g.
After separation, the interphase and all of the Nycoprepâ were collected
and washed four times with 0.9% NaCl + 0.13% ethylenediamine
tetraacetic acid + 1% bovine serum albumin. Then CD14 expression was
assessed by ¯ow cytometry and was > 95%. Monocytes were cultured for
8 d in medium containing 500 IU per ml human recombinant granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) (Leucomax,
Novartis Pharma AG, Basel, Switzerland) and 500 IU per ml human
recombinant IL-4 (Gibco). On the other hand, monocytes from the
same donor were cultured with GM-CSF 500 IU per ml, recombinant
IL-4 500 IU per ml, and reducing agents such as 5 mM, 10 mM, or
50 mM 2-ME or the anti-oxidant DTT 0.5 mM to obtain IDEC in 24-
well plastic plates. On day 2, the cultures were fed with fresh medium,
500 IU per ml GM-CSF and 500 IU per ml IL-4 and the respective
amount of 2-ME for the generation of IDEC on days 4, 6, and 8.
Ampli®cation of mRNA and analysis of transcripts Total RNA
was extracted after 8 d of culture from highly puri®ed monocyte-derived
dendritic cells (MoDC) or IDEC using Trizol (Life Technologies,
Eggenstein, Germany) following the manufacturer's instructions. Reverse
transcription reactions were performed using 1 mg of total RNA.
Denaturation at 94°C for 40 s was followed by annealing of the primers
at 55°C for 30 s and extension at 72°C for 30 s. A ®nal extension phase
of 5 min was added. Speci®c primer sequences for each gene were as
follows:
Human b-actin: sense, 5¢-GAG CGG GAA ATC GTG CGT GAC
ATT-3¢; anti-sense, 5¢-GAT GGA GTT GAA GGT AGT TTC GTG-
3¢, yielding a fragment of 240 bp.
Human FceRIa: sense, 5¢-CTG TTC TTC GCT CCA GAT GGC
GT-3¢; anti-sense, 5¢-TAC AGT AAT GTT GAG GGG CTC AG-3¢
(fragment of 536 bp).
Human FceRIg: sense, 5¢-CCA GCA GTG GTC TTG CTC TTA C-3¢
and anti-sense: 5¢-GCA TGC AGG CAT ATG TGA TGC C-3¢ (fragment
of 338 bp).
Ampli®cation was performed on a Perkin-Elmer Gene Amp PCR
System 9600 (Applied Biosystems, Weiterstadt, Germany) polymerase
chain reaction (PCR) System 9600 thermocycler (Applied Biosystems,
Weiterstadt, Germany). The PCR cycle numbers for the ampli®cation of
the respective cDNA were 25 for b-actin and 30 for FceRIa and
FceRIg. Speci®c PCR fragments were separated on a 1% agarose gel and
visualized using ethidium bromide staining. The PCR products were
evaluated semiquantitatively by comparing the ratio of the speci®c
products vs the b-actin band by digital image analysis using the WinCam
system (Cybertech, Berlin, Germany).
FceRI-dependent activation of IDEC On day 8, IDEC were
washed and incubated at 2.5 3 105 cells per ml in 24-well ¯at-bottomed
culture plates in medium containing 10 mg per ml anti-FceRI MoAb
(F(ab¢)2 22E7 or isotype-matched control mIgG1 for 1 h at 37°C.
Excessive IgE was removed, and surface-bound IgE was cross-linked by
addition of medium containing goat anti-mouse IgG (GaM-IgG)
alternative Ig cells were loaded with 1 mg/1 ml human mycloma IgE for
1 hour. As previously described (Jurgens et al, 1995). In blocking
experiments, cells were preincubated with anti-CD23 (9P.25; 5 mg per
ml) and lactose (0.2 M, 15 min) in order to block eBP binding and
CD23 before loading with IgE or with blocking antibody to FceRI (15-
5; 1 mg per ml) and lactose (0.2 M, 15 min). As a control, the cells were
incubated with goat anti-mouse IgG (GaM-IgG) MoAb alone.
Statistical analysis Statistical differences were determined by paired
Student's t test using SPSS for Windows 8.5. p < 0.05 was considered
statistically signi®cant.
Figure 4. IDEC from lesional skin of AEDS and IDEC generated from monocytes of atopic donors are phenotypically similar. The
expression of surface markers of IDEC isolated from lesional skin of AEDS is indicated as ¯uorescence intensity (log) on the x-axis and CD1a
expression as ¯uorescence intensity on the y-axis (upper panel). In comparison, the expression of these surface molecules detectable on IDEC generated
in vitro are shown (lower panel). This is a representative experiment of n = 10.
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RESULTS
FceRI surface expression of DC can be in¯uenced by
reducing agents exclusively in atopic donors Addition of
reducing agents, such as 2-ME 5 mM, 10 mM, and 50 mM
signi®cantly enhanced the FceRI surface expression of IDEC of
atopic donors obtained on day 8 of the IL-4/GM-CSF driven
in vitro culture, with the highest FceRI expression achieved by
incubation with 50 mM 2-ME (Fig 1 A,B). In contrast, no
signi®cant increase of the FceRI surface expression could be
achieved in nonatopic donors (Fig 1 A,C). Neither the viability
(81.72 6 2.78% viable cells on day 8 of culture without and
86.67 6 1.69% viable cells on day 8 of culture with 50 mM 2-ME)
nor the CD1a surface expression of IDEC generated in the
presence of 2-ME changed (78.53 6 5.22% CD1a-positive cells on
day 8 of culture) in comparison with the control condition without
2-ME (71.86 6 8.26% CD1a-positive cells on day 8 of culture).
To determine, whether this effect could be induced by reducing
agents in general and reversed by an oxidative milieu, the reducing
agent DTT 0.5 mM or the pro-oxidative H2O2 were added to the
culture. In accordance with the previous observations, addition of
0.5 mM DTT led to a signi®cant upregulation of the FceRI surface
expression on day 8 of culture, whereas a rapid downregulation of
the FceRI surface expression was induced by the addition of H2O2
(Fig 2).
Upregulation of the FceRI complex by reducing agents
results from an enhanced FceRIg expression For the human
system, it has been reported that the presence of FceRIg is necessary
for the surface expression of FceRIa and the function of the
receptor complex.
To determine, whether the source of FceRIg of IDEC in the
presence of 2-ME was in part the result of an enhanced mRNA
transcription, we performed semiquantitative analyses of PCR
products from human FceRIa and FceRg of MoDC and IDEC.
Whereas MoDC and IDEC displayed the same amount of FceRIa
transcripts, the level of FceRIg transcripts was 50% higher in IDEC
than in MoDC, as evaluated by densitometry (Fig 3A). Transcripts
for the FceRI b-chain could neither be detected in MoDC nor in
IDEC (data not shown). To con®rm these results, we evaluated the
FceRIa surface expression in parallel to the intracellular pool of
FceRIa and the intracellular amount of FceRIg by ¯ow cytometric
staining. First, we analyzed the intracellular amount of the a-chain
and the FceRIa surface expression and permeabilized the cells with
low digitonin concentrations to evaluate the intracellular content of
FceRIg. Whereas the intracellular levels of FceRIa were high in
both conditions, with and without 2-ME, the amount of FceRIg
was signi®cantly higher in IDEC generated in the presence of 50 mM
2-ME (Fig 3B). The extracellular and intracellular expression of
CD16, which is known to associate with FceRIg was below 5% in
MoDC and IDEC cultured with reducing agents (data not shown),
excluding the fact that the upregulation of the g-chain by 2-ME leads
to a general enhancement of structures containing g-chains.
In vitro generated FceRIhigh IDEC display a phenotype
highly similar to IDEC isolated from lesional skin of atopic
eczemadermatitis syndrome In the next series of experiments,
we compared the typical phenotypical characteristics of IDEC
isolated from lesional skin of AEDS with IDEC generated in vitro
(Fig 4). Detailed phenotypical analyses of IDEC generated in the
presence of 50 mM 2-ME evaluated by ¯ow cytometry revealed that
FceRIhigh IDEC from atopic donors were Langerin and Lag
Figure 5. The most striking difference of MoDC and IDEC generated in vitro is the surface expression of FceRI. MoDC and IDEC did
not differ in the surface expression of the costimulatory molecules CD80, CD86, MHC class I, MHC class II, or CD83. The most striking difference
of MoDC and IDEC generated in vitro of monocytes of the same atopic donor is the elevated FceRI surface expression of IDEC. The surface marker
pro®le of MoDC and IDEC on day 8 of culture is shown as overlay histogram (gray curve) in correlation to the respective isotype control (black
curve). The ¯uorescence intensity (log) is indicated on the x-axis, the number of CD1a positive MoDC or IDEC is indicated on the y-axis. CLA,
cutaneous lymphocyte antigen; MR, mannose receptor; E-cadh., E-cadherin. This is a representative experiment of n = 15.
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negative and lack the Langerhans cell speci®c Birbeck granules.
This was evaluated additionally by electron microscopic staining
(data not shown). The typical surface marker pro®le displayed by
MoDC and in vitro generated FceRIhigh IDEC from the same
atopic donor is shown in Fig 5. As characteristics of cells localized
in the epithelial tissue, IDEC express the epithelial antigen E-
cadherin and skin-homing antigen cutaneous lymphocyte antigen
on their cell surface. In summary, IDEC generated in vitro from
atopic donors expressed FceRI in high amounts and were therefore
phenotypically similar to IDEC from lesional skin of AEDS.
FceRI of IDEC generated in vitro is functional In order to
investigate, whether FceRI on IDEC generated in vitro could be
ef®ciently loaded with IgE by incubation with human myeloma
IgE for 1 h, blocking studies were performed.
IDEC were preincubated with lactose and MoAb 9P.25 to
prevent the binding of IgE to the e-binding proteins (eBP) and
CD23, respectively. The IgE binding capacity was correlated with
the surface expression of FceRI. As a proof of concept,
preincubation of IDEC with a blocking antibody to FceRI (15-
5) and lactose abrogates IgE binding to these cells. These
experiments identi®ed FceRI as the main IgE binding structure
on IDEC generated in vitro (Fig 6).
Engagement of FceRI on IDEC on day 8 of culture induces
the production of proin¯ammatory cytokines and
chemokines As data about the cytokine and chemokine
production induced by FceRI activation of IDEC on day 8 of
culture are not available due to the rapid downregulation
expression FceRI from the surface during the in vitro culture, we
analyzed the quality of the cytokine and chemokine production of
FceRI-activated IDEC. We could clearly show that FceRI
activation enhanced the production of proin¯ammatory cytokines
and chemokines such as IL-1a, IL-1B, MCP-1, MCP-3,
RANTES, TN1-a, and MIP-1a.
DISCUSSION
In this study, we provide a reliable in vitro model to generate
MoDC in a reducing micromilieu displaying a functional FceRI
receptor complex and a phenotype highly similar to IDEC, which
Figure 6. FceRI on IDEC binds monomeric IgE in high amounts. The FceRI surface expression of IDEC on day 8 of culture is shown as
overlay histogram (A). On day 8 of culture, no constitutive IgE binding of IDEC could be detected by staining with FITC-labeled anti-IgE MoAb (B).
In blocking experiments, IDEC were preincubated with blocking antibody to CD23 (9P.25; 5 mg per ml) and 0.5 lactose. Then IDEC were loaded
with 0.5 lactose mg per ml human myeloma IgE and stained with FITC-labeled anti-IgE MoAb (C). Additionally, preincubation of IDEC with
blocking antibody to FceRI and lactose completely abrogates IgE binding (D). Taken together, IDEC bind IgE via FceRI in high amounts on their
cell surface.
Figure 7. FceRI stimulation of IDEC induces the production of
pro-in¯ammatory cytokines. Stimulation of FceRI with MoAb
against FceRI induces an enhanced production of pro-in¯ammatory
cytokines and chemokines. The percentage of the intracellular cytokine
production of CD1a+ IDEC is indicated on the y-axis. White bars
indicate unstimulated IDEC on day 8 of culture, black bars indicate
IDEC, which have been stimulated via FceRI for a time period of 18 h,
gray bars indicate IDEC stimulated via mIgG and GaM-IgG, hatched
bars indicate IDEC stimulated with GaM-IgG alone; n = 8. From these
data we conclude that FceRI on IDEC generated in vitro is functional as
cross-linking of FceRI induces an increased cytokine production.
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have been detected in the skin lesions of AEDS patients
(Wollenberg et al, 1996). In addition, IDEC generated in vitro
display typical characteristics of cells located in the epithelial tissue,
such as E-cadherin and cutaneous lymphocyte antigen, which is
required for the homing of cells within the epithelia (Ebner et al,
1998; Nakamura et al, 1998).
Most interestingly, engagement of FceRI on IDEC induces the
production of proin¯ammatory cytokines and chemokines, which
are typically found in high amounts in the epidermal skin lesions of
in¯ammatory skin diseases, such as AEDS (Pastore et al, 2000). The
observation that IDEC could be generated exclusively from
monocytes of atopic donors with a high FceRI surface expression
implies that a preformed pool of all components of the FceRI
complex is necessary for the FceRI upregulation and enhanced
transcription of the FceRIg chains induced by reducing agents, such
as 2-ME. Research work over the last years has focused on a better
understanding of the mechanisms regulating FceRI surface expres-
sion on human effector and antigen-presenting cells. Borkowski et
al (2001) designed an in vitro model to establish the minimal cellular
requirements for the regulation of FceRI by IgE on the monocytic
cell line U937 and NIH3T3 transfectants. IgE binding to the a-
chain is the minimal requirement for the induction of FceRI
upregulation in this model and the mechanism of the upregulation
is the result of a combination of the stabilization of the receptor at
the cell surface, the use of a preformed receptor pool, and a
continued basal level of protein synthesis.
In this context the role of thiolic anti-oxidants as modulators of
nuclear factor-kB activation and inhibitors of the DC maturation
should be addressed (Ardeshna et al, 2000). DC generated in the
presence or absence of 2-ME did not differ signi®cantly in the
CD83 expression, the expression of costimulatory molecules, and
in their stimulatory capacity toward autologous and allogeneic T
cells assessed in mixed lymphocyte experiments (data not shown).
Therefore, we conclude that the enhanced FceRI surface expres-
sion on IDEC achieved by incubation with 2-ME does not result
from an inhibition of the maturation of these cells by anti-oxidative
agents; however, the relevance of a putative in¯uence of thiolic
anti-oxidants on nuclear factor-kB mediated signal transduction
events of IDEC generated with 2-ME has to be elucidated in more
detail in studies of the future.
The effect of reducing agents, such as DTT, on living cells have
been studied in depth by Braakman et al (1992). They could show
that changes in the cellular redox state induced by agents, such as 2-
ME or DTT interfere with the folding and export of proteins located
in the endoplasmic reticulum. In addition, molecular chaperones of
the cytosol are known to be redox regulated and their activity
accelerates in a reducing environment (Angelini et al, 2002). This
could lead to an enhancement of the intracellular transport
mechanisms of ag-chain associates to the cell surface in our
model.
As another aspect, a limiting role of cysteine for the cell cycle
progression of human peripheral blood lymphocytes has been
described by different research groups (Sido et al, 2000). Cell
culture media used for the generation of MoDC usually contain
only cystin and the addition of 2-ME leads to the formation of
mixed disul®des of cystin derived from cystin (Sido et al, 2000). In
this way, the amount of cysteine available throughout the in vitro
culture for IDEC is enhanced and could be used for the de novo
synthesis of FceRIg, which consists of two cysteine residues per g-
chain (Kinet, 1999). In vivo, the reducing extracellular micro-
environment could be created by antigen-presenting DC, which
produce anti-oxidants such as thioredoxin in high amounts after
contact with antigen-speci®c T cells (Jakob et al, 1999).
In conclusion, the modulation of the FceRI surface expression
by the redox state of the microenvironment could contribute to the
upregulation of FceRI on IDEC in favor of a higher antigen-
presenting capacity of these cells, which might lead to the
ampli®cation of immune responses in allergic in¯ammatory skin
diseases, such as AEDS.
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